Meeting
2013 ASCO Annual Meeting
Assessment of absolute lymphocyte count (ALC) as a predictor of progression-free survival (PFS) and overall response rate (ORR) in metastatic melanoma (MM) patients (pts) treated with high-dose interleukin-2 (HD IL-2).
Authors
Jeffrey Thomas Yorio
The University of Texas MD Anderson Cancer Center, Houston, TX
Jeffrey Thomas Yorio , Patricia S Fox , Richard Wayne Joseph , Roland Bassett Jr., Michael A. Davies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9096)
DOI
10.1200/jco.2013.31.15_suppl.9096
Abstract #
9096
Poster Bd #
53A
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Final report of a pilot trial combining ipilimumab and adoptive cell therapy.
First Author: John Mullinax
Poster
2016 ASCO Annual Meeting
Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.
First Author: MarnixMarnix Heimen Geukes Foppen
Poster
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
First Author: Adriana Matutino Kahn
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Response rate and safety of standard-dose nivolumab with reduced-dose ipilimumab in metastatic melanoma.
First Author: Inderjit Mehmi